Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Stacey Knox (NPI 1750353447)

Field	Value
Entity Type	Individual
Organization	Stacey Knox
Address	4101 Tiger Lily Rd Ste 100
City	Lincoln
State	NE
ZIP	68516
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	February 6, 2006

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

This provider’s code mix is consistent with an active hematology/oncology infusion and diagnostic practice: the top revenue drivers are oncology biologics J9271 ($387K, 29.2%), J9299 ($353.3K, 26.7%), and bone-modifying agent J0897 ($142.6K, 10.8%), alongside chemotherapy administration (96413, $31.8K) and PET/CT imaging (78815, $79.9K). Additional support codes—lab panels (80053, $9.6K), CBC (85025, $11.5K), flow cytometry (88185, $14K) and bone marrow biopsy (38222, $6.7K)—underscore a vertically integrated diagnosis-to-treatment workflow in oncology care.

Revenue concentration is high: the precomputed top-3 Medicare codes by revenue account for 66.7% of this provider’s total Medicare revenue, indicating that pembrolizumab (J9271) and nivolumab (J9299) are the primary revenue drivers. This level of concentration suggests financial sensitivity to utilization or pricing changes in a small set of high-cost drugs.

Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $1.4M while Medicaid shows none (no Medicaid billing on file). The absence of Medicaid activity means the provider’s reimbursement exposure, patient mix, and utilization profile will be driven almost entirely by Medicare policies and beneficiary demand.

Competitive standing across key drugs is mixed. J9271 ranks #1299 of 1841 providers nationally (29th percentile; typical, unremarkable volume) and J9299 ranks #255 of 505 (49th percentile; typical, unremarkable volume), indicating a modest national footprint for those immunotherapies, while J0897 ranks #1603 of 10057 (84th percentile; typical, unremarkable volume), reflecting relatively stronger placement for denosumab compared with peers.

Visit and ancillary volumes include several high-percentile appearances that signal above-typical outpatient activity: 99214 generated $72.6K (834 claims) and ranks #17738 of 479517 providers (96th percentile; notably above typical national volume), and 36415 (blood draw) ranks in the 97th percentile with $9.4K. These elevated E/M and phlebotomy rankings suggest a steady panel of actively managed, frequently seen Medicare patients.

Operational risk and opportunity: reliance on high-revenue biologics (J9271 and J9299) concentrates revenue around a small set of drugs, which creates negotiation leverage with payers but also vulnerability to shifts in drug utilization, biosimilar uptake, or reimbursement policy. Given the code mix, any changes to coverage or unit pricing for these agents could materially affect Medicare revenue.

Local market and access implication from Medicaid absence: with no Medicaid billing on file, the provider may not be participating in Medicaid or is not capturing Medicaid patients, which limits access for low-income populations and concentrates commercial and Medicare patient flows. For payers and network planners, this profile flags the provider as a Medicare-centric oncology resource rather than a broad payer-participating community oncology practice.

Tenure and stability: the NPI was enumerated 2006-02-06 (~20 years ago), indicating a long-established presence in the market. This duration supports interpretation of the reported patterns as established practice behavior rather than a short-lived or newly opened billing entity.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

71 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	9,000	$40	$387K
J9299	Injection, nivolumab, 1 mg	14,720	$20	$353.3K
J0897	Injection, denosumab, 1 mg	7,920	$20	$142.6K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	70	$1,080	$79.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	830	$90	$72.6K
J1439	Injection, ferric carboxymaltose, 1 mg	36,000	$1	$36K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	340	$90	$31.8K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	320	$90	$27.5K
78816	The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The…	20	$1,090	$26.2K
74177	The provider performs computed tomography of the abdomen and pelvis with contrast material to diagnose the cause of abdominal or pelvic pain or other abnormalities of the internal organs.	110	$160	$17.4K

Showing 1–10 of 71

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 71 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Stacey Knox — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

71 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	22	30	14,400	$40	$671.6K
J9299	9	10	19,300	$20	$444.5K
J0897	22	200	2,040	$20	$62.7K
J2506	16	20	460	$90	$40.5K
78815	26	60	70	$380	$32.7K
J1439	9	30	25,880	$1	$26.4K
J9217	49	50	110	$130	$20.6K
J0885	9	10	3,180	$10	$19.2K
96413	22	80	60	$90	$18.2K
74177	110	160	170	$80	$15.3K

Showing 1–10 of 71

Related Providers

Other providers that share a Tax Identification Number (TIN) with Stacey Knox, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bryan Medical Center	NE	General Acute Care Hospital	$0	$56.9M
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
The Physician Network	NE	Family Medicine Physician	$0	$3.1M
Eric Avery	NE	Hematology & Oncology Physician	$3.1M	$0
Kailash Mosalpuria	NE	Hematology & Oncology Physician	$2.9M	$0
Chi Health Clinic Specialty, LLC	NE	Hospitalist Physician	$0	$2.6M
York General Hospital	NE	Critical Access Hospital	$0	$2.4M
Madhu Midathada	NE	Hematology & Oncology Physician	$2.3M	$0
Scott Mcham	NE	Hematology & Oncology Physician	$1.9M	$0
Sakeer Hussain	IA	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Stacey Knox, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Melvin Churchill	NE	Rheumatology Physician	$4.8M	$0
Lincoln Radiology Group PC	NE	Diagnostic Radiology Physician	$0	$4.5M
Elite Professionals Home Care LLC	NE	Home Health Agency	$0	$4.2M
Rick Chatwell	NE	Rheumatology Physician	$3.5M	$0
Lincoln Pediatric Group LLC	NE	Pediatrics Physician	$0	$2.3M
Nebraska House Call Physicians, P.C.	NE	Internal Medicine Physician	$0	$1.7M
Steven Dunder	NE	Hematology & Oncology Physician	$1.7M	$0
Urology Surgical Center LLC	NE	Ambulatory Surgical Clinic/Center	$1.4M	$190.5K
Wallace Peterson	NE	Hematology & Oncology Physician	$1.5M	$0
Irfan Vaziri	NE	Medical Oncology Physician	$1.4M	$0

Stacey Knox — Billing Profile & Reimbursement Data

Sign up for Stacey Knox — Billing Profile & Reimbursement Data policy alerts

Stacey Knox — Billing Profile & Reimbursement Data

Sign up for Stacey Knox — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References